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A variety of scientific and regulatory challenges may be encountered during the commercialization of a 
monoclonal antibody process.  These challenges may be compounded when the product is licensed-in.  In this 
work, we present case studies detailing a series of experiences and lessons learned during the 
commercialization of a licensed-in monoclonal antibody process.  The work will cover topics including 
qualification of scale-down models, troubleshooting scale-up and tech transfer, mitigation strategies for process 
performance variability, and demonstration of clonality. A variety of experimental and statistical methodologies 
were implemented to address these concerns, including application of multivariate data analysis.  Details of the 
methodologies will also be provided to demonstrate their application to troubleshooting of commercial upstream 
fed-batch production processes. 
 
